Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232934 | 0.79 | — | — | |
| SCHEMBL12751334 | 0.79 | ALDH1A1 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL14776843 | 0.77 | HRH3 (0.30) | — | |
| SCHEMBL2230476 | 0.75 | ELANE (0.35) | ALDH1A1 | |
| SCHEMBL15069120 | 0.73 | KDM4E (0.31) | KDM4EALDH1A1 | |
| SCHEMBL1012697 | 0.72 | ALDH1A1 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL12691979 | 0.71 | RAPGEF4 (0.30) | — | |
| SCHEMBL819223 | 0.66 | HRH3 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL811692 | 0.65 | GABRA1 (0.38) | ALDH1A1 | |
| SCHEMBL13510522 | 0.64 | UGT2B17 (0.37) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8350051-B2 | Process for producing alpha-hydroxyketone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110178309-A1 | PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178309-A1 | PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND | BCKDK, PDK4, HK1 | KDM4E 840/4885ALDH1A1 37/4885 |
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MSMO1, MGMT | KDM4E 1423/4885ALDH1A1 113/4885 |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MGMT, BBOX1 | KDM4E 2236/4885ALDH1A1 182/4885 |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | ADH5, ADH1A, ADH1C | KDM4E 620/4885ALDH1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.